Manufacturers of certain insulin and protein products must now follow new rules with the regulatory transition of their drugs to biological products. FDA regulatory partner Kellie Combs (Washington, D.C.) were quoted in three separate Pink Sheet articles on the anticipated impact that the FDA transition provision will have on regulatory exclusivity, patent litigation, and the biologics and biosimilars market.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.